Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Immune system disorders – page 14

  • 1 664 clinical trials
  • 562 recruiting
  • 293 conditions
  • 29 countries

Conditions in this area

293 conditions with trials, the busiest first

Colitis ulcerative120Crohn's disease94Asthma89Dermatitis atopic89HIV infection78Rheumatoid arthritis75Systemic lupus erythematosus63Multiple sclerosis59Psoriasis54Psoriatic arthropathy46Myasthenia gravis44Type 1 diabetes mellitus41Systemic scleroderma40Conjunctivitis allergic34Idiopathic pulmonary fibrosis34Sjogren's syndrome31Cardiac amyloidosis29Interstitial lung disease29Immune thrombocytopenia27Endocrine ophthalmopathy26IgA nephropathy24Vitiligo24Hereditary angioedema22Axial spondyloarthritis21+269

Clinical trials in Immune system disorders

1 664 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 664 clinical trials

Immunoglobulin G4 related disease

Recruiting

A study to evaluate the safety and effects of inebilizumab in children and adolescents with immunoglobulin G4-related disease

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:Inebilizumab
  • Sponsor:Amgen Inc.

Still's disease+1

Recruiting

A study to evaluate the long-term safety of apremilast in children with oral ulcers from Behçet’s disease or juvenile psoriatic arthritis

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Apremilast
  • Sponsor:Amgen Inc.

Systemic lupus erythematosus

Recruiting

Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Litifilimab
  • Sponsor:Biogen Idec Research Limited

Interstitial lung disease

Recruiting

Efficacy and Safety of Subcutaneous Belimumab in Adults with Connective Tissue Disease-Associated Interstitial Lung Disease

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Lupus nephritis

Recruiting

A Study of Prednisolone, Mycophenolate Mofetil and Voclosporin Compared to Prednisolone and Mycophenolate Mofetil in Patients with Lupus Nephritis

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Voclosporin
  • Sponsor:Amsterdam UMC Stichting

Endocrine ophthalmopathy

Recruiting

Study of K1-70 compared to placebo for patients with active thyroid eye disease from Graves' disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Human IgG1 monoclonal antibody against thyrotropin receptor
  • Sponsor:Av7 Limited

Cardiac amyloidosis

Recruiting

A study of coramitug compared to placebo for people with heart failure caused by transthyretin amyloid cardiomyopathy

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Coramitug
  • Sponsor:Novo Nordisk A/S

Anti-neutrophil cytoplasmic antibody positive vasculitis

Recruiting

A Study of CND261 for Patients with Active ANCA-Positive Vasculitis That Has Not Responded to Previous Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Fraunhofer Institute For Translational Medicine And Pharmacology ITMP

Encephalitis autoimmune

Recruiting

Testing 18F-DPA-714 PET scan as a marker of brain inflammation in patients with autoimmune encephalitis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:N,N-DIETHYL-(2-(4-(2-(18F)FLUOROETHOXY)PHENYL)-5,7-DIMETHYLPYRAZOLO(1,5-A)PYRIMIDINE-3-YL)ACETAMIDE
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Myasthenia gravis

Recruiting

Study of oral cladribine compared to placebo for patients with generalized myasthenia gravis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Merck Healthcare KGaA

Giant cell arteritis

Recruiting

A Study Using [AL[18F]F]FAPI-74 PET Scan to Improve Diagnosis and Monitoring of Giant Cell Arteritis in Patients with This Blood Vessel Disease

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:UZ Leuven

Mite allergy

Recruiting

A study testing dust mite allergy extracts from Dermatophagoides pteronyssinus and Dermatophagoides farinae for patients with allergic rhinoconjunctivitis with or without controlled asthma

Registered drug
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:LETI Pharma S.L.U.

Substances studied in this area

The therapies tested most often in Immune system disorders trials.

Sodium Chloride61 clinical trialsRituximab50 clinical trialsPrednisone47 clinical trialsAdalimumab40 clinical trialsEmtricitabine40 clinical trialsTenofovir Alafenamide38 clinical trialsTocilizumab38 clinical trialsMethotrexate37 clinical trialsPrednisolone35 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.